FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Dr. Reddy's Laboratories Limited Stock AnalysisComprehensive stock analysis for Dr. Reddy's Laboratories Limited (RDY) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisRDY
RDY
Dr. Reddy's Laboratories Limited
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
RDY
Home🔹Stocks🔹Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited

🇺🇸RDY•NYSE

Dr. Reddy's Laboratories Limited

🇺🇸RDY•NYSE
Market cap
$9.91B
Sentiment

Your view on RDY

Mkt Cap
$9.91B
Sentiment
Your view
RDY
Dr. Reddy's Laboratories Limited
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
RDY
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Dr. Reddy's Laboratories Limited

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Erez Israeli
Headquarters
8-2-337, Road No. 3, Hyderabad, IN
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Erez Israeli
Headquarters
8-2-337, Road No. 3, Hyderabad, IN
Description

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments.

The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business.

The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements.

Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation.

The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology.

The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Dr. Reddy's Laboratories Limited, and the rating behind it. RDY last traded at $11.90, 29.3× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Dr. Reddy's Laboratories Limited. Starting points for Dr. Reddy's Laboratories Limited: P/E 29.3, EPS $39.76, beta 0.25 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Dr. Reddy's Laboratories Limited. Dr. Reddy's Laboratories Limited paid $0.08 per share over the last year — a 0.7% yield at the current $11.90 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Dr. Reddy's Laboratories Limited. Trailing twelve-month EPS for Dr. Reddy's Laboratories Limited stands at $39.76. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Dr. Reddy's Laboratories Limited. Dr. Reddy's Laboratories Limited has reported as a listed company since 2001. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Dr. Reddy's Laboratories Limited valued side by side against its closest peers. Dr. Reddy's Laboratories Limited is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Dr. Reddy's Laboratories Limited, and how their positions are changing. At a $9.91B market value, institutional positions materially move Dr. Reddy's Laboratories Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Dr. Reddy's Laboratories Limited executives and directors. Shares of Dr. Reddy's Laboratories Limited have traded between $12.26 and $16.17 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Dr. Reddy's Laboratories Limited. Dr. Reddy's Laboratories Limited is a $9.91B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Dr. Reddy's Laboratories Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Dr. Reddy's Laboratories Limited. Coverage tracks Dr. Reddy's Laboratories Limited within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • BMRN — BioMarin Pharmaceutical Inc.
  • EHC — Encompass Health Corporation
  • ELAN — Elanco Animal Health Incorporated
  • ENSG — The Ensign Group, Inc.
  • EXEL — Exelixis, Inc.
  • NBIX — Neurocrine Biosciences, Inc.
  • RVMD — Revolution Medicines, Inc.
  • RVTY — Revvity, Inc.

More Drug Manufacturers - Specialty & Generic companies

  • TRUFF — Red Light Holland Corp.
  • TSMRF — Tsumura & Co.
  • PAHC — Phibro Animal Health Corporation
  • PAIOF — Paion AG
  • PBF.CN — Planet Based Foods Global Inc.
  • PBFFF — Planet Based Foods Global Inc.
  • PCLO.V — PharmaCielo Ltd.
  • PCLOF — PharmaCielo Ltd.
  • PCRX — Pacira BioSciences, Inc.
  • PCYN — Procyon Corporation
  • PEMTF — Thoughtful Brands Inc.
  • PER.AX — Percheron Therapeutics Limited

ETFs holding Dr. Reddy's Laboratories Limited

  • EDOG — ALPS Emerging Sector Dividend Dogs ETF (2.13%)
  • EMOP — Alliance BernsteinAB Emerging Markets Opportunities ETF (2.05%)
  • VMIN.AX — Vanguard Global Minimum Volatility Active ETF (0.61%)
  • NSI — National Security Emerging Markets Index ETF (0.54%)
  • EELV — Invesco S&P Emerging Markets Low Volatility ETF (0.36%)
  • EMEQ — Macquarie Focused Emerging Markets Equity ETF (0.25%)
  • DFEV — Dimensional - Emerging Markets Value ETF (0.11%)
  • QEMM — State Street SPDR MSCI Emerging Markets StrategicFactors ETF (0.10%)

News

Latest Market News